Medicus Pharma MDCX 深 沪
已收盘 08-14 16:00:00 美东时间
0.2801
-0.074
-20.88%
华盛通- 最 高0.362
- 今 开0.354
- 成交量 275.41万股
- 最 低 0.28
- 昨 收 0.354
- 总市值 1587.00万
- 52周最高 3.05
- 市盈率 静 --
- 换手率 4.86%
- 52周最低 0.25
- 委 比 97.72%
- 总股本 5665.82万
- 历史最高 8.94
- 量 比 2.47
- 振 幅 23.16%
- 历史最低 0.25
- 每 手 1
- 风险率 0.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Medicus Pharma GAAP EPS of -$0.21
Medicus Pharma press release (MDCX): Q2 GAAP EPS of -$0.21. Cash, cash equivalents, and restricted cash: $25.2M as of June 30, 2026. More on Medicus Pharma Ltd. Seeking Alpha’s Quant Rating on Medicus...
08-13 22:38
Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 51.16 percent increase over losses of $(0.43) per share from the same period last year.
08-13 06:02
Medicus Pharma Receives FDA's Study May Proceed Letter Authorization For Its Investigational New Drug For SKNJCT-005 To Start Phase 2b Clinical Study To Treat Gorlin Syndrome
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the U.S. Food and Drug Administration ("FDA") has completed its safety r...
07-27 20:18
Medicus Pharma Announces Positive FDA Feedback For Its Optimized Phase 2 Clinical Trial Of Teverelix In Men Following A First Episode Of Acute Urinary Retention
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it has received written feedback from the U.S. Food and Drug Administrat...
07-16 19:33
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Medicus Pharma Ltd. announced FDA feedback and IRB approval for its optimized Phase 2 study of Teverelix® for preventing recurrent acute urinary retention in men. The redesigned study, ANT-2111-02, will enroll ~126 patients (down from ~390) and evaluate Teverelix DP's effects on prostate volume and urinary function. The study aims to generate decision-grade evidence, optimize dose and route, and support future development and partnerships. FDA re...
07-16 11:30
Medicus Pharma To Present Showcase SkinJect Registrational Strategy, Teverelix Precision Medicine Program At 2026 Bio International Conference
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it will participate in the 2026 Bio International Conference, being hel...
06-22 19:37
Medicus Pharma Submits IND Application To DOH For PRECISION-E2, Phase 2a Genomics-Enabled Clinical Trial Evaluating Teverelix In Women With Symptomatic Endometriosis In UAE
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced submission of an Investigational New Drug (IND) application to the Department...
06-11 19:34
Medicus Pharma Submits Protocol SKNJCT-005 To FDA Under Existing IND Application, For SkinJect Into Registrational Development For Patients With Gorlin Syndrome
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today
06-03 20:06
